Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Rohit Loomba, Erin Morgan, Lynnetta M. Watts, Shuting Xia, Lisa A. Hannan, Richard S. Geary, Brenda F. Baker, Sanjay Bhanot
Topics & Concepts
Fatty liverTolerabilityMedicinePlaceboInternal medicineClinical endpointAlcoholic liver diseaseGastroenterologyClinical trialAdverse effectDiseaseCirrhosisPathologyAlternative medicineLiver Disease Diagnosis and TreatmentLipid metabolism and biosynthesisDiabetes, Cardiovascular Risks, and Lipoproteins